SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Altre lingue Shenzhen Salubris Pharmaceuticals Co., Ltd.

Azioni

002294

CNE100000FW8

Prezzo di chiusura Shenzhen Stock Exchange Altri mercati azionari 00:00:00 04/12/2023			Variaz. 5gg	Var. 1 gen.
32,63 ^CNY	-1,45%		-0,67%	-0,67%

30/10	Shenzhen Salubris Pharmaceuticals Co., Ltd. riporta i risultati degli utili per i nove mesi conclusi il 30 settembre 2023	CI
09/10	Salubris Pharmaceuticals ottiene l'approvazione per la sperimentazione delle compresse SAL0120	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10
Salubris Pharmaceuticals Gets Nod to Trial SAL0120 Tablets	09/10
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08
Salubris Pharmaceuticals Gets US FDA Nod for Arthritis Drug Trial	18/07
Precision Scientific announced that it has received funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.	26/06
Salubris Pharma Gets Nod for Kidney Disease Tablets	12/06
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for A Shares for the Year 2022	27/04
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for 2022	19/04
Salubris Pharmaceuticals' 2022 Adjusted Profit Down 11%	19/04
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	18/04
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Dividend for the Year 2022	29/03
Salubris Pharmaceuticals Plans to Spin Off Medical Instrument Unit for Listing	28/03
Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to Spin-Off Medical Instrument Unit of Shenzhen Salubris Pharmaceuticals Co Ltd.	28/03
Salubris Pharmaceutical Co., Ltd. announced that it expects to receive CNY 26 million in funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.	18/01
Salubris Pharmaceuticals to Begin Clinical Trial of Anti-COVID-19 Tablets	04/01
Kexing Enrols Subjects in Phase II Clinical Trial of Oral COVID-19 Drug	03/01
Shenzhen Salubris Pharmaceuticals Gets Nod for Anti-Tumor Drug Trial	30/12
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	2022
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	2022
Salubris Pharma Gets Nod to Hold Clinical Trials of Diabetes Drug Candidate	2022

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Transcript Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shenzhen Salubris Pharmaceuticals Co., Ltd.

Azioni

002294

CNE100000FW8

Altre lingue

Filtri